For Healthcare Professionals

Professional Education

The Lymphoma Research Foundation offers a wide range of lymphoma-focused educational activities designed to increase the knowledge, skills and performance of healthcare professionals and to maximize the quality of care for lymphoma patients.

Lymphoma Rounds

The Lymphoma Rounds program provides a forum for local practicing physicians from academic and community medical centers to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients.

Scientific Workshops

LRF’s scientific workshops help to mobilize the research community, overcome systemic challenges and speed the progress by which new treatments are developed.


Resources for Your Patients

LRF provides a comprehensive series of educational resources and services that can be helpful for your patients, and valuable supplements to your current practices.

Resources for Researchers

LRF remains dedicated to finding a cure for lymphoma through an aggressively-funded program for researchers. Ongoing research opportunities include:

Real-World Perspectives in Managing CLL Treatment

Support for this activity has been provided through educational grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.

Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings—though of course beneficial for CLL patients—represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances in the use of cytogenetic and molecular tests to stratify risk and determine prognosis.

This interactive activity presents the points of view of doctors and patients on issues relating to current challenges in CLL care. Each point of view is followed by a brief discussion that will help oncologists and hematologist-oncologists select the most appropriate targeted therapies, taking into account patient genetics, treatment adverse events, and previous treatments.

Jointly provided by: